NEW DELHI, Nov 9: In a major relief for cancer patients and their families, the government has implemented revised prices for 1,364 anti-cancer medicine formulations from November 9, 2026, in an effort to make life-saving treatment more affordable and reduce the financial burden associated with oncology care.
The decision, taken through the National Pharmaceutical Pricing Authority (NPPA), is expected to result in annual savings of approximately Rs 3,540.38 crore for consumers. The revised pricing structure seeks to control excessive trade margins and ensure that patients do not have to pay unnecessarily high prices for essential cancer medicines.
The move comes amid growing concerns over the rising cost of cancer treatment in India, where patients often face substantial expenses involving medicines, diagnostic investigations, hospitalisation, chemotherapy and other specialised procedures.
For many households, the financial consequences of a cancer diagnosis extend well beyond the initial treatment period. Patients may require repeated treatment cycles, prolonged medication and regular medical monitoring, making affordability a critical factor in accessing appropriate care.
The latest government intervention is intended to address one important component of these expenses by bringing down the prices of a wide range of anti-cancer formulations.
According to the reported figures, the revised rates cover 1,364 formulations, while the broader pricing exercise is expected to provide significant relief to patients purchasing medicines through pharmacies and healthcare facilities.
The development is being viewed as an important step towards strengthening access to affordable cancer treatment and improving the effectiveness of India’s pharmaceutical pricing framework.
The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, has capped trade margins on 137 identified non-scheduled anti-cancer medicines at 30 per cent of their maximum retail price (MRP). The measure is aimed at controlling excessive markups across the pharmaceutical distribution chain and ensuring that patients receive medicines at more reasonable prices.
According to government figures, 85 pharmaceutical companies had submitted revised prices for 1,364 formulations covering 121 drugs by November 8. Among these, 679 brands reported price reductions exceeding 50 per cent, while the highest reduction in MRP stood at 96.45 per cent.
The revised prices reflect the government’s efforts to make expensive cancer medicines more accessible, particularly for patients requiring prolonged treatment and specialised therapies.
Major reductions in commonly used cancer medicines
The revised pricing exercise covers several important categories of oncology medicines, including targeted therapies, immunotherapy products and supportive medicines used during cancer treatment.
Among the notable examples is Bevacizumab, a medicine used in the treatment of certain lung, colorectal, ovarian and cervical cancers. Its different branded formulations have recorded substantial reductions.
For instance, the price of Bryxta, manufactured by Zydus Lifesciences, was reduced from Rs 25,995 to Rs 3,318. Similarly, Reliance Life Sciences’ BevaciRel saw its price fall from Rs 24,079 to Rs 3,985.
Another example is Denosumab, which is used in certain cancer patients to help prevent bone-related complications. The price of DenOsteoRel, manufactured by Reliance Life Sciences, was reduced from Rs 24,955 to Rs 6,240.
These examples illustrate the potential financial relief for patients purchasing expensive oncology medicines.
Trade margin rationalisation behind the decision
The pricing intervention was undertaken under Paragraph 19 of the Drugs (Prices Control) Order, 2013, which empowers authorities to regulate medicine prices in the public interest.
The expert committee constituted by the Directorate General of Health Services recommended the intervention after examining the pricing structures of identified non-scheduled anti-cancer medicines.
Under the mechanism, trade margins have been restricted to 30 per cent, helping prevent excessive price increases between manufacturers and the final point of sale.
The government has clarified that the objective is not to disrupt the pharmaceutical supply chain but to ensure reasonable pricing while protecting legitimate manufacturing revenues.
Companies are also expected to maintain existing production and supply levels to avoid shortages of essential medicines.
Patients advised to verify revised prices
The government has encouraged consumers to check the updated maximum retail prices before purchasing anti-cancer medicines.
Patients can use the Pharma Sahi Daam mobile application and the NPPA’s official website to verify the applicable rates.
Retailers, hospital pharmacies and medical institutions are required to implement the revised prices from November 9. Hospitals must also ensure that medicines supplied directly to their patients reflect the updated rates.
Consumers who encounter overcharging can register complaints through the Pharma Jan Samadhan portal or contact the NPPA helpline at 1800-111-255.
The authorities have also directed manufacturers to communicate revised price lists to distributors, retailers and hospitals to ensure that the benefits reach patients without unnecessary delays.
A significant step towards affordable cancer treatment
Cancer treatment frequently involves multiple stages of medical intervention, including surgery, chemotherapy, radiation therapy, immunotherapy and long-term medication. The financial burden can become particularly difficult for families when patients require expensive medicines over extended periods.
The latest intervention is expected to provide relief by reducing the cost of several formulations used in cancer management.
However, medicine prices represent only one component of overall treatment expenditure. Diagnostic procedures, hospital admissions, specialist consultations and other supportive services continue to contribute to the financial burden.
The government has therefore emphasised the importance of improving access to affordable medicines as part of its broader healthcare objectives.
The pricing initiative also highlights the role of regulatory oversight in ensuring that essential medicines remain accessible without allowing excessive commercial markups.
With revised rates now in force, the focus will be on effective implementation, transparent pricing and uninterrupted availability of medicines across healthcare facilities.
The government expects the intervention to generate annual consumer savings of approximately Rs 3,540.38 crore, making it one of the significant recent measures aimed at reducing the financial pressure associated with cancer care in India.